Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics, Inc.    SRPT

SAREPTA THERAPEUTICS, INC.

(SRPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Reco.

Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

11/25/2020 | 08:30am EST

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, Dec. 2, 2020 at 3:30 p.m. E.T.

The presentation will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics
At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.  

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.
Investors:
Ian Estepan, 617-274-4052, iestepan@sarepta.com

Media:
Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com


Primary Logo


© GlobeNewswire 2020
All news about SAREPTA THERAPEUTICS, INC.
01/13SAREPTA THERAPEUTICS : How a collaboration in the lab led to a seat at the table..
PU
01/13SAREPTA THERAPEUTICS : Genevant Sciences Unveil Research Collaboration for Neuro..
MT
01/13Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration fo..
GL
01/12INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
01/12SAREPTA THERAPEUTICS : Citigroup Downgrades Sarepta Therapeutics to Neutral from..
MT
01/11SAREPTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regu..
AQ
01/11SAREPTA THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Conf..
AQ
01/11SAREPTA THERAPEUTICS : UBS Cuts Sarepta Therapeutics to Neutral From Buy, PT to ..
MT
01/11ELI LILLY, TWITTER, NIO : What to Watch When the Stock Market Opens Today
DJ
01/09SRPT EQUITY ALERT : ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of S..
PR
More news
Financials (USD)
Sales 2020 530 M - -
Net income 2020 -516 M - -
Net cash 2020 823 M - -
P/E ratio 2020 -14,4x
Yield 2020 -
Capitalization 7 648 M 7 648 M -
EV / Sales 2020 12,9x
EV / Sales 2021 9,95x
Nbr of Employees 743
Free-Float 95,2%
Chart SAREPTA THERAPEUTICS, INC.
Duration : Period :
Sarepta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 121,75 $
Last Close Price 96,92 $
Spread / Highest target 107%
Spread / Average Target 25,6%
Spread / Lowest Target -24,7%
EPS Revisions
Managers and Directors
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Wilsey Chairman
Ian M. Estepan Executive VP, Chief Financial & Accounting Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Louise Rodino-Klapac Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS, INC.-43.15%7 648
GILEAD SCIENCES, INC.14.97%83 961
VERTEX PHARMACEUTICALS0.97%62 055
WUXI APPTEC CO., LTD.18.76%60 054
REGENERON PHARMACEUTICALS10.84%56 517
BEIGENE, LTD.38.16%32 552